The Wegovy pill is oral semaglutide 25 mg taken once a day. In OASIS 4, the trial behind its approval, adults with overweight or obesity and no diabetes lost a mean 13.6% of body weight by week 64 against 2.2% on placebo (PMID 40934115). The injection’s comparable figure is STEP 1, where semaglutide 2.4 mg once weekly produced 14.9% over 68 weeks in a similar population (PMID 33567185).
Those two numbers came from two separate trials, not from a head-to-head, and the daily tablet differs from the weekly injection in more than the needle. It has its own dose ladder, its own administration rules and its own price.
- Same molecule. The tablet carries SNAC, an absorption enhancer that gets semaglutide through the stomach lining.
- OASIS 4: 25 mg daily, 64 weeks, no diabetes, -13.6% against -2.2% on placebo, in 307 participants.
- Four tablet strengths, 1.5 mg, 4 mg, 9 mg and 25 mg, escalating every 30 days rather than every four weeks.
- The administration rules have no injection equivalent: empty stomach, plain water, then 30 minutes before anything else.
- Gastrointestinal adverse events in OASIS 4 were 74.0% against 42.2% on placebo, a familiar profile rather than a milder one.
What the pill actually is
Semaglutide is a peptide, and peptides normally do not survive the stomach. The tablet solves that with salcaprozate sodium, known as SNAC, which buffers the local acidity and briefly increases absorption through the stomach lining. That mechanism is the reason for every unusual instruction attached to the product: it works only in an empty stomach with a small amount of plain water.
The FDA approved the Wegovy pill for chronic weight management, making it the first oral GLP-1 licensed for weight loss, with the United States launch in early January 2026. It is the same active molecule as the Wegovy injection, at a completely different milligram scale, because so little of an oral dose is absorbed.
The trials, and why they are not a head-to-head
| Trial | Formulation and dose | Population | Primary timepoint | Mean weight change |
|---|---|---|---|---|
| OASIS 4 (PMID 40934115) | Oral semaglutide 25 mg daily | 307 adults, overweight or obesity, no diabetes | Week 64 | -13.6% (placebo -2.2%) |
| OASIS 1 (PMID 37385278) | Oral semaglutide 50 mg daily | 667 adults, overweight or obesity, no diabetes | Week 68 | -15.1% (placebo -2.4%) |
| STEP 1 (PMID 33567185) | Semaglutide 2.4 mg injected weekly | 1961 adults, overweight or obesity, no diabetes | Week 68 | -14.9% (placebo -2.4%) |
Nobody has randomised the same people to the tablet or the injection and compared them, so the gap between 13.6% and 14.9% is a gap between trials. OASIS 4 was much smaller than STEP 1, ran four weeks shorter to its primary endpoint, and enrolled at 22 sites in four countries. Any of those could move a percentage point.
The 50 mg arm in OASIS 1 is a useful third data point: a dose twice the approved one produced 15.1%, which is close to the injection and to the 25 mg result. Whatever separates these formulations, it is not a large difference in ceiling.
Two numbers circulate for the pill
You will see 13.6% and 16.6% attached to the same trial. Both are OASIS 4. The 13.6% figure counts everyone as randomised, including participants who stopped the drug, which is the estimand the primary endpoint used. The 16.6% figure describes what happened among participants who stayed on treatment. Neither is wrong, and the first is the one to compare against STEP 1, which was analysed the same way.
The dose ladders do not resemble each other
The tablet climbs in 30-day blocks through four strengths, and the injection climbs in four-week steps through five. Below is what each label describes. The escalation on either product can be held longer when a step is not tolerated, and both are prescriber decisions rather than schedules to run yourself.
| Step | Wegovy pill (daily) | Wegovy injection (weekly) |
|---|---|---|
| 1 | 1.5 mg, days 1 to 30 | 0.25 mg, weeks 1 to 4 |
| 2 | 4 mg, days 31 to 60 | 0.5 mg, weeks 5 to 8 |
| 3 | 9 mg, days 61 to 90 | 1 mg, weeks 9 to 12 |
| 4 | 25 mg, from day 91 | 1.7 mg, weeks 13 to 16 |
| 5 | No higher strength | 2.4 mg maintenance, from week 17 |
Roughly three months to the maintenance dose either way. The practical difference is the count: 90 tablets before the maintenance dose against about 16 injections. Adherence is a daily question on one product and a weekly one on the other, and OASIS 4’s two headline figures are partly a measure of exactly that. The weekly ladder is set out in full in our semaglutide dosage chart.
Rules the injection does not have
These come from the product information and are descriptive, not instructions to follow without a prescriber.
- Taken in the morning on an empty stomach, with plain water only, up to about 4 ounces.
- Then at least 30 minutes before food, other drinks or any other oral medication.
- Swallowed whole. The label states the tablet should not be split, crushed or chewed, because the effect on absorption is unknown and SNAC works as an intact system.
- One tablet a day. The labelled strengths are not designed to be combined, and doubling up on a lower strength is not the same as the higher one, because oral semaglutide absorption is not proportional.
Missing the 30-minute window is not a safety event, but it does reduce how much drug is absorbed. That is a real difference from the injection, where absorption does not depend on what the person did that morning.
Tolerability is not the reason to choose the tablet
A common assumption is that swallowing the drug avoids the side effects of injecting it. The OASIS 4 data does not support that. Gastrointestinal adverse events were reported by 74.0% of the oral semaglutide group against 42.2% on placebo, and the trial investigators described the profile as consistent with what the 2.4 mg injection produced in earlier trials. It is the same molecule reaching the same receptors.
What the tablet removes is the injection itself, along with the refrigeration and the weekly injection-site routine. For people who will not or cannot inject, that is the whole argument, and it is a good one. We went through what the trials logged on symptoms in semaglutide side effects.
Cost
As of late September 2026 the manufacturer’s self-pay pharmacy lists the pill from $149 a month at the starting strength and $299 at the 9 mg and 25 mg doses, against $349 a month for the standard injection doses. So the tablet is cheaper at the bottom of the ladder and modestly cheaper at the top, on published cash pricing. The wider set of options is in our piece on the cheapest GLP-1 without insurance.
What would 13.6% mean for you?
Put your own starting weight against the OASIS 4 and STEP 1 averages.
FAQ
Is the Wegovy pill as effective as the injection?
No trial has compared them directly. OASIS 4 recorded a mean 13.6% weight loss on oral semaglutide 25 mg at week 64, and STEP 1 recorded 14.9% on the 2.4 mg injection at week 68, in similar populations but separate trials of very different size. The two results are close enough that the honest answer is that nobody has measured the difference.
Can you cut the Wegovy pill in half?
The product information says the tablet should not be split, crushed or chewed. The SNAC absorption enhancer works as part of an intact tablet, and the effect of breaking it is not established. Any question about your own dose belongs with the prescriber who wrote it.
Can you take two Wegovy pills at once to reach a higher dose?
The label specifies one tablet daily and the strengths are not designed to be combined. Oral semaglutide absorption is not proportional to the number of tablets swallowed, so two lower-strength tablets do not stand in for one higher-strength tablet.
What is the Wegovy pill dose schedule?
Four strengths taken once daily: 1.5 mg for the first 30 days, then 4 mg, then 9 mg, then 25 mg from about day 91, with each increase made as tolerated. Escalation can be delayed when a step is not tolerated.
Why does the Wegovy pill have to be taken on an empty stomach?
Because the absorption enhancer SNAC only works in a small volume of liquid against the stomach lining. Food and other drinks dilute that environment, which is why the label specifies plain water and a 30-minute gap before anything else.
Does the pill cause fewer side effects than the injection?
Not by the trial data. In OASIS 4, gastrointestinal adverse events occurred in 74.0% of the oral semaglutide group against 42.2% on placebo, a profile the investigators described as consistent with the injectable trials.
Sources
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PMID: 40934115
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. PMID: 37385278
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Wegovy (semaglutide) tablets and injection, prescribing information, Novo Nordisk. Dosage and administration, dosage forms and strengths.
- FDA approval of the Wegovy pill for chronic weight management, the first oral GLP-1 licensed for weight loss; United States launch January 2026.
- NovoCare Pharmacy published self-pay price guides for the Wegovy pill and Wegovy injection, checked 29 September 2026.
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.